Low-voltage Areas Defragmentation in Sinus Rhythm for Radiofrequency Ablation of Persistent Atrial Fibrillation
NCT ID: NCT04045067
Last Updated: 2023-09-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
212 participants
OBSERVATIONAL
2019-09-25
2023-09-11
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Cardiac Surgical Treatment by Radiofrequency Ablation on Valvular Patients: Efficacy at 3 Months
NCT00259623
Clinical Prognosis of Patients With Atrial Fibrillation During Radiofrequency Ablation
NCT03564327
PROSPective Evaluation of Outcome After CatheTer Ablation in Atrial Fibrillation
NCT05009797
Noninvasive 3D Mapping in Persistent Atrial Fibrillation, to Describe Modifications of the Arrhythmogenic Substrate After Pulmonary Vein Isolation and Identify Potential Predicting Factors of Ablation Success
NCT04229160
Safety Monitoring of Patients Having Pulmonary Vein Ablation
NCT00590668
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group 1
A group of patients who have pulmonary vein isolation alone, without low-voltage areas identified.
Isolation of pulmonary veins
Low voltage areas are identified and treated by radiofrequency. Atrial fibrillation is treated by heat produced by an electric current: radio frequency. This is an intervention that consists of blocking abnormal electrical activity, especially in the pulmonary veins.
Group 2
A group of patients who have pulmonary veins isolation alone, with low-voltage areas identified but the complementary defragmentation will not be carried out.
Isolation of pulmonary veins
Low voltage areas are identified and treated by radiofrequency. Atrial fibrillation is treated by heat produced by an electric current: radio frequency. This is an intervention that consists of blocking abnormal electrical activity, especially in the pulmonary veins.
Group 3
A group of patients who have pulmonary veins isolation, with low-voltage areas identified and the complementary defragmentation will be carried out.
Isolation of pulmonary veins
Low voltage areas are identified and treated by radiofrequency. Atrial fibrillation is treated by heat produced by an electric current: radio frequency. This is an intervention that consists of blocking abnormal electrical activity, especially in the pulmonary veins.
Ablation by radiofrequency of low-voltage areas
The defragmentation is guided by a map of fragmented potentials, made through a topography catheter, to locate the most abnormal areas that are the target of ablation.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Isolation of pulmonary veins
Low voltage areas are identified and treated by radiofrequency. Atrial fibrillation is treated by heat produced by an electric current: radio frequency. This is an intervention that consists of blocking abnormal electrical activity, especially in the pulmonary veins.
Ablation by radiofrequency of low-voltage areas
The defragmentation is guided by a map of fragmented potentials, made through a topography catheter, to locate the most abnormal areas that are the target of ablation.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients participating in a biomedical research can participate in this study.
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
French Cardiology Society
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Antoine LEPILLIER, MD
Role: PRINCIPAL_INVESTIGATOR
Centre Cardiologique du Nord
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Centre Hospitalier Universitaire d'Angers
Angers, , France
Clinique de l'Infirmerie Protestante de Lyon
Caluire-et-Cuire, , France
Centre Hospitalier Saint Joseph Saint Luc
Lyon, , France
Hôpital Saint-Joseph
Marseille, , France
Hôpital Privé Beauregard
Marseille, , France
Clinique Ambroise Paré
Neuilly-sur-Seine, , France
Hôpital Universitaire Pitié Salpêtrière
Paris, , France
Centre Cardiologique du Nord
Saint-Denis, , France
Clinique Saint Gatien
Tours, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2019-02
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.